Press release in respect of audited (standalone and consolidated) financial results for the quarter and financial year ended 31 March 2026

Revenue growth above 20%EBITDA margin compressionProfit growth above 25%Results View source PDF Explain this filing

SURAKSHA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹322.00

prior close

₹320.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-5.2% vs market

Healthcare Service Provider peers, median of 26sector-0.4%-4.6% vs sector

On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 4.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.4

10m

-6.4

15m

-6.2

30m

-6.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.1-5.2-0.4-4.6

Next day

-7.5+1.7-9.1-1.3-6.2

-8.4+2.4-10.8-0.6-7.8

-9.9+2.4-12.3+1.8-11.7

-10.2+1.7-12.0+0.2-10.5

-13.0+0.6-13.6-3.0-10.1

-9.2+1.9-11.1-2.1-7.1

15d

-16.2+4.9-21.1-0.6-15.6

-13.5+8.9-22.4+1.1-14.6

-19.6+7.5-27.1-5.5-14.1

-0.0+13.6-13.6+0.7-0.8

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 26Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suraksha Diagnostic reported strong revenue growth with Total Income rising 22.5% YoY to ₹3,136 million in FY26. EBITDA grew 15.8% to ₹986 million, though EBITDA margin compressed from 33.8% to 31.8% due to investments in newly launched centres. PAT increased only 1.4% to ₹314 million, with Q4 PAT declining 14.1% YoY to ₹62 million. Test volumes surged 22% to 8.16 million tests, driven by network expansion adding 2 hubs, 11 spoke centres, and 4 PPP projects. Average revenue per test rose 15.6% in Q4 to ₹421. The company noted mature centres (>2 years old) maintain stable 36-37% EBITDA margins, while newer centres are in ramp-up phase.

Likely market impact

Revenue growth is healthy but margin compression and minimal PAT growth may concern investors focused on profitability; the stock could face mixed reaction as expansion costs weigh on near-term earnings.